The FDA has cleared nContact to market EPi-Sense, a next-generation version of the company's VisiTrax heart ablation system. The newly cleared technology comes with advanced sensors, which transmit electrical signals to help electrophysiologists position the device better when performing cardiac ablation surgery.
NContact scores 510(k) clearance for next-gen cardiac system
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|